Also, even though Leo mentions the ABSSSI market which B will do well in, but the real $$ for antibiotics will come from other indications. ABSSSI is just the gateway, not the end game.

Regarding K, I just want to reiterate he made a point to note that it is very unusual for DF to offer to extend the trial. Also, Leo said he needs to wait until his next meeting with the FDA before giving us more K info. I forget if that was for January or just early 2016, but that means we could get a K update soon.